Exercise Capacity in CTEPH Improved With Treprostinil
December 27, 2018 Share this content: Fewer patients in the high-dose treprostinil group had clinical worsening. Patients with chronic thromboembolic pulmonary hypertension (CTEPH) treated with high-dose subcutaneous treprostinil, a prostacyclin analogue, had increased 6-minute walk distances compared with low-dose subcutaneous treprostinil, according to the results of a study published in Lancet Respiratory Medicine. Six-minute walk… Read More »